6.22
-0.23 (-3.57%)
| Previous Close | 6.45 |
| Open | 6.39 |
| Volume | 125,867 |
| Avg. Volume (3M) | 121,873 |
| Market Cap | 152,326,544 |
| Price / Sales | 35.78 |
| Price / Book | 17.03 |
| 52 Weeks Range | |
| Earnings Date | 2 Aug 2023 - 7 Aug 2023 |
| Profit Margin | -264.71% |
| Operating Margin (TTM) | -1,289.41% |
| Diluted EPS (TTM) | -0.480 |
| Quarterly Revenue Growth (YOY) | -35.30% |
| Total Debt/Equity (MRQ) | 37.06% |
| Current Ratio (MRQ) | 1.23 |
| Operating Cash Flow (TTM) | -15.86 M |
| Levered Free Cash Flow (TTM) | -7.19 M |
| Return on Assets (TTM) | -41.39% |
| Return on Equity (TTM) | -217.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | DURECT Corporation | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | -1.79 |
|
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe . |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 11.82% |
| % Held by Institutions | 22.32% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |